ME Jan 2025 7.000 call
| Previous close | 0.1000 |
| Open | 0.0400 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 7.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0400 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.26k |
Barrons.com23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid
In what looks like a potentially downbeat ending to 23andMe journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojcicki, who controls more than 20% of 23andMe’s stock, with about 49% voting control, told the company that she is considering making an offer to buy the shares she doesn’t already own. Neither Wojcicki nor the company have commented on what she might be willing to pay, but investors appear skeptical that it will come at a premium price.
Bloomberg23andMe Jumps as CEO Floats Taking DNA Tester Private
(Bloomberg) -- DNA testing firm 23andMe Holding Co.’s shares soared after Chief Executive Officer Anne Wojcicki said she’s considering taking the struggling company private, less than three years after it began selling shares.Most Read from BloombergDubai Grinds to Standstill as Flooding Hits CityElon Wants His Money BackSingapore Loses ‘World’s Best Airport’ Crown to QatarRecord Rainfall in Dubai? Blame Climate Change, Not Cloud SeedingRed Lobster Considers Bankruptcy to Deal With Leases and La
GlobeNewswire23andMe announces CEO’s intention to pursue a potential take-private
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E
